In this issue:
CheckMate 744: a transplant-free approach for younger relapsed Hodgkin lymphoma
INO-CD22: real-world inotuzumab ozogamicin in relapsed/refractory B-ALL
Real-world oral azacitidine maintenance in AML
CAVEAT final analysis: chemotherapy + venetoclax in elderly AML
Ibrutinib + nivolumab in relapsed CNS lymphoma
BOVen (zanubrutinib, obinutuzumab, venetoclax) in treatment-naïve TP53-altered MCL
IMPROVE: paused vs. continued BTKi during COVID-19 vaccination in chronic lymphocytic leukaemia
Venetoclax + daunorubicin & cytarabine in newly diagnosed AML
Reduced-intensity induction & thiotepa-busulfan-based ASCT in primary CNS lymphoma
CLIA (cladribine, idarubicin, cytarabine) in relapsed/refractory AML
Please login below to download this issue (PDF)